Merdury Biopharmaceutical

Merdury Biopharmaceutical FCF Conversion

The FCF Conversion Rate (FCF/EBITDA) of Merdury Biopharmaceutical (6932.TWO) as of Oct 18, 2026 is 86.47 %. In the previous year, FCF Conversion Rate (FCF/EBITDA) was 90.59 % — a change of -4.54% (lower).

FCF Conversion

86.47 %

YoY

-4.54%

Last updated:

FCF Conversion Rate (FCF/EBITDA) of Merdury Biopharmaceutical is 2025 86.47 % . FCF Conversion Rate (FCF/EBITDA) of Merdury Biopharmaceutical was 2024 90.59 % . It decreases by -4.54% lower compared to the previous year.

The Merdury Biopharmaceutical FCF Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Conversion
Date
FCF Conversion
Jan 1, 2019
98.99 TWD
Jan 1, 2020
103.33 TWD
Jan 1, 2021
231.57 TWD
Jan 1, 2022
302.38 TWD
Jan 1, 2023
127.16 TWD
Jan 1, 2024
90.59 TWD
Jan 1, 2025
86.47 TWD
The Merdury Biopharmaceutical FCF Conversion history
YEARFCF ConversionYoY
86.47 %-4.54%
90.59 %-28.76%
127.16 %-57.95%
302.38 %+30.58%
231.57 %+124.10%
103.33 %+4.38%
98.99 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Merdury Biopharmaceutical Stock analysis

What does Merdury Biopharmaceutical do? Merdury Biopharmaceutical Corp is a pharmaceutical company based in Taipei, Taiwan, operating within the Health Care sector. The company has a small workforce of 13 employees and went public on December 23, 2022, with its ticker listed as 6932.TWO. Merdury Biopharmaceutical Corp focuses on developing drugs that address unmet medical needs, difficult generic drugs, and second-class new drugs. The company utilizes a self-developed drug development platform called StackDose, which enables the creation of tablets with controlled dissolution properties, allowing for either immediate or sustained drug release. This technology supports the development of products such as Sildenafil, Metformin, Tadalafil, Zolpidem, angina treatments, migraine medications, and multi-ingredient antihypertensive drugs. These products are primarily marketed and sold in Taiwan and the United States. The company's website is https://merdury.com, providing further information about its operations and offerings. Merdury Biopharmaceutical Corp operates as a publicly traded entity with a focus on innovative pharmaceutical solutions within the Taiwanese and U.S. markets. Merdury Biopharmaceutical is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Merdury Biopharmaceutical stock

FCF Conversion Rate (FCF/EBITDA) of Merdury Biopharmaceutical is 86.47 % in 2025.

FCF Conversion Rate (FCF/EBITDA) of Merdury Biopharmaceutical changed from 90.59 % to 86.47 %, representing a -4.54% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of FCF Conversion Rate (FCF/EBITDA) Merdury Biopharmaceutical since 2006 – with annual values, charts, and detailed analysis.

FCF conversion measures how effectively EBITDA converts to free cash flow. Higher conversion indicates efficient capital allocation and low maintenance costs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare FCF Conversion Rate (FCF/EBITDA)'s Merdury Biopharmaceutical with sector peers and the industry average to assess whether it is attractive.

To evaluate FCF Conversion Rate (FCF/EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for FCF Conversion Rate (FCF/EBITDA).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Cash Flow — Merdury Biopharmaceutical

Operating Cash FlowCapital ExpendituresFree Cash FlowFCF per ShareDividends PaidShare BuybacksInvesting Cash FlowFinancing Cash FlowCapEx / RevenueCash Flow per ShareStock-Based CompensationChange in Working CapitalAcquisitions (Net)Net Change in CashCapEx/OCFFCF/Net IncomeFCF ConversionCash ConversionTotal Shareholder PayoutCapEx/D&A

All Key Metrics — Merdury Biopharmaceutical